• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

    6/23/25 7:13:00 AM ET
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ILMN alert in real time by email

    Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach

    Positions Illumina to achieve growth in a large, expanding market

    Illumina and SomaLogic have partnered in proteomics co-development since late 2021

    SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ:LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

    "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future," said Jacob Thaysen, chief executive officer of Illumina. "Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling."

    This transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan® Proteomics Assay onto Illumina's high-throughput next-generation-sequencing (NGS) platforms. Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics will accelerate the technology development roadmap for proteomics and reduce time and cost of proteomic research.

    "We are taking the scalability of NGS into proteomics," continued Thaysen. "Illumina will remain an open, accessible, and enabling NGS platform. The Company is committed to maintaining and supporting its existing proteomics partnerships as well as continuing to develop the sequencing ecosystem and supporting a wide variety of multiomics solutions."

    Scientific evidence* presented over the past year demonstrates the strength of SomaLogic's proteomics offerings in the areas of plexity, scalability, and technical reproducibility. In addition, researchers can generate significant and pivotal insights with high sensitivity, high throughput, and thousands of protein markers in a single experiment.

    SomaLogic has approximately 250 employees worldwide working in commercial, R&D, lab operations, manufacturing, and other roles. The company's Boulder, Colorado, facilities—including a CLIA- and CAP-certified lab, office, and manufacturing space—will be part of the purchase. SomaLogic has a global footprint serving customers.

    This transaction brings SomaLogic's aptamer-based affinity proteomics platform into Illumina's portfolio, enhancing Illumina's presence in a high-growth area within the proteomics market. The kitted NGS-based panels business will add a high-margin consumables revenue stream. Based on the projected closing date, Illumina expects this business to become profitable in 2027 on a non-GAAP operating income basis, and for non-GAAP operating margins to be in line with Illumina in 2028.

    Completion of the transaction is subject to customary closing conditions, including the receipt of required regulatory clearance. The parties intend to make the necessary filing under the Hart-Scott-Rodino Act in the United States in due course. Illumina expects to close the transaction in the first half of 2026. Until then, the companies will continue to operate as separate and independent entities. 

    Goldman Sachs and Co. LLC is serving as financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. Centerview Partners LLC is serving as financial advisor to Standard BioTools, and Freshfields LLP and Richards, Layton & Finger P.C. are serving as its legal counsel. UBS Investment Bank is serving as financial advisor to the Special Committee of the Standard BioTools Board of Directors.

    Use of forward-looking statements

    This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the completion of the proposed transaction on the anticipated terms and timeline, or at all, including the ability of the parties to obtain required regulatory clearance—such as under the Hart-Scott-Rodino Act in the United States or from government authorities that may have or assert jurisdiction outside the United States—and to satisfy other conditions to closing; (ii) the future conduct and growth of the business and the markets in which we operate, including the proteomics market; (iii) the success of products and services competitive with our own; (iv) our ability to successfully integrate SomaLogic into our existing operations and SomaLogic's technology and products into our portfolio; (v) our ability to sell SomaLogic's products and further develop SomaLogic's technology; (vi) our ability to successfully manage partner and customer relationships in the proteomics market; (vii) our ability to manufacture robust instrumentation and consumables including SomaLogic's products; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) challenges inherent in developing, manufacturing, and launching new products and services; and (x) customer uptake of, and satisfaction with, new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Brian Blanchett

    [email protected]

    Media:

    Christine Douglass

    [email protected]

    *References:

    1. Rooney MR, Chen J, Ballantyne CM, et al. Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink. medRxiv. Preprint posted online July 12, 2024. doi:10.1101/2024.07.11.24310161



    2. Kirsher DY, Chand S, Phong A, Nguyen B, Szoke BG, Ahadi S. The current landscape of plasma proteomics: technical advances, biological insights, and biomarker discovery. bioRxiv. Preprint posted online February 19, 2025. doi: 10.1101/2025.02.14.638375

     

    Cision View original content:https://www.prnewswire.com/news-releases/illumina-to-acquire-somalogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy-302488151.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ILMN
    $LAB

    CompanyDatePrice TargetRatingAnalyst
    Illumina Inc.
    $ILMN
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Standard BioTools Inc.
    $LAB
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Illumina Inc.
    $ILMN
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    Illumina Inc.
    $ILMN
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    Illumina Inc.
    $ILMN
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Illumina downgraded by Scotiabank with a new price target

      Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

      7/11/25 8:11:04 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Citigroup reiterated coverage on Illumina with a new price target

      Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

      3/4/25 8:10:42 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00

      2/28/25 9:03:13 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    $LAB
    SEC Filings

    See more
    • SEC Form 8-K filed by Illumina Inc.

      8-K - ILLUMINA, INC. (0001110803) (Filer)

      6/23/25 9:24:49 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/23/25 9:11:17 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/20/25 4:16:03 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ILMN
    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Cunningham Everett covered exercise/tax liability with 4,248 shares, decreasing direct ownership by 9% to 41,942 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      7/8/25 5:59:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      7/2/25 4:26:43 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Cox Troy was granted 94,592 shares, increasing direct ownership by 58% to 256,412 units (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/24/25 7:00:22 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ILMN
    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

      7/21/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

      SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

      7/10/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities

    $ILMN
    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      3/4/25 8:19:51 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ILMN
    $LAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Standard BioTools Appoints Alex Kim as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

      11/7/24 8:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology

    $ILMN
    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

      SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      11/14/24 3:32:10 PM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ILMN
    $LAB
    Financials

    Live finance-specific insights

    See more
    • Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

      SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

      7/21/25 7:00:00 AM ET
      $LAB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

      SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

      7/10/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

      Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

      6/18/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care